KBC Group
DYN icon

KBC Group’s Dyne Therapeutics DYN Stock Holding History

KBC Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$85K Buy
5,297
+1,892
+56% +$43.5K ﹤0.01% 1485
2026
Q2 		$76K Hold
3,405
– – ﹤0.01% 1552
2026
Q1 		$62K Buy
3,405
+270
+9% +$4.66K ﹤0.01% 1570
2025
Q4 		$61K Hold
3,135
– – ﹤0.01% 1564
2025
Q3 		$40K Hold
3,135
– – ﹤0.01% 1694
2025
Q2 		$30K Hold
3,135
– – ﹤0.01% 1701
2025
Q1 		$33K Hold
3,135
– – ﹤0.01% 1846
2024
Q4 		$74K Buy
3,135
+978
+45% +$28.9K ﹤0.01% 1709
2024
Q3 		$77K Buy
2,157
+751
+53% +$29.9K ﹤0.01% 1456
2024
Q2 		$50K Hold
1,406
– – ﹤0.01% 1611
2024
Q1 		$40K Buy
+1,406
New +$31.8K ﹤0.01% 1667

Other funds holding DYN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

KBC Group's DYN Position: Q3 2026 in Review

KBC Group increased its Dyne Therapeutics (DYN) stake by 56% in Q3 2026, buying an estimated $43.5K and bringing the position to 5,297 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

KBC Group first reported a position in DYN in Q1 2024 and has held it in 11 quarters since. 179 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • KBC Group held 5,297 shares of Dyne Therapeutics worth $85K as of Q3 2026.
  • KBC Group bought 1,892 Dyne Therapeutics shares in Q3 2026, an estimated $43.5K.
  • Dyne Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1485 holding.
  • KBC Group first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 179 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.